Τhe role of sacubitril/valsartan therapy on renal function and glucose metabolism in chronic heart failure patients

Chrysοhoou, Christina; Tousoulis, Dimitris

doi:10.15761/iod.1000196

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, it is usually attributed to higher concentration of active peptides which could not be degraded by inactive neprilysin like BNP, bradykinin and glucagon-like peptide-1 (GLP-1) (Fig. 3) [28][29][30][31][32][33]. Although the use of sacubitril/valsartan seems to be beneficial in patients with diabetes by potentiating antihyperglycaemic acting of endogenous GLP-1, the use of ARNI in concomitant treatment with GLP-1 long-acting analogues may be harmful in patients with both diabetes and heart failure.…”

Section: Effects Of Arni On Glycaemia Control In Patients With Diabetesmentioning

confidence: 99%

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

Książczyk

Lelonek

2019

Heart Fail Rev

View full text Add to dashboard Cite

It is over 4 years since the Prospective Comparison of angiotensin receptor/neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial was published in New England Journal of Medicine. The PARADIGM-HF trial was the one that contributed to the official approval to use ARNI simultaneously with cardiac resynchronisation therapy (CRT) or implantable cardioverter-defibrillator (ICD) in patients who receive optimal medical treatment and still presented NYHA II-IV class symptoms according to the 2016 European Society of Cardiology Guidelines for the diagnosis and treatment of acute and chronic heart failure. The aim of this article is to summarise current knowledge on the activity of ARNI in a selected group of patients with heart failure with reduced ejection fraction (HFrEF) based on a recent PARADIGM-HF subanalysis in the field of renal function in patients with and without chronic kidney disease, glycaemia control in patients with diabetes, ventricular arrhythmias and sudden cardiac death and health-related quality of life. This article includes also recently announced findings on the TRANSITION study which revealed that HFrEF therapy with ARNI might be safely initiated after an acute decompensated heart failure episode, including patients with heart failure de novo and ACEI/ARB naïve, both hospitalised or shortly after discharge, in contrary to the PARADIGM-HF trial, where patients had to be administered a stable dose of an ACEI/ARB equivalent to enalapril 10 mg a day for at least 4 weeks before the screening.

show abstract

Section: Effects Of Arni On Glycaemia Control In Patients With Diabetesmentioning

confidence: 99%

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

Książczyk

Lelonek

2019

Heart Fail Rev

View full text Add to dashboard Cite

show abstract

Role of sacubitril/valsartan in glycemic control of cardiac patients with diabetes: a systematic review

AbduRehman¹,

Alghamrawi²

2021

IJMDC

View full text Add to dashboard Cite

Τhe role of sacubitril/valsartan therapy on renal function and glucose metabolism in chronic heart failure patients

Cited by 2 publications

References 26 publications

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

Role of sacubitril/valsartan in glycemic control of cardiac patients with diabetes: a systematic review

Contact Info

Product

Resources

About